Thymosin α-1 · Pep IQ

Origin & Background

From Thymus to Global Medicine

Thymosin was discovered in 1966 by Allan Goldstein and colleagues, who found a lymphocyte-stimulating factor in calf thymus. After years of isolation and purification work, Thymosin α-1 was separated from the broader thymosin fraction 5 mixture in 1977 — and found to be 10 to 1,000 times more potent than the parent mixture. It is a 28 amino acid peptide produced by thymic epithelial cells and is one of the most conserved immune-signalling molecules across mammalian species.

Its synthetic form, thymalfasin (brand name: Zadaxin), has been approved in over 35 countries and carries FDA orphan drug status for malignant melanoma, chronic active hepatitis B, DiGeorge syndrome with immune defects, and hepatocellular carcinoma. A 2024 comprehensive review covering over 30 clinical trials and more than 11,000 human subjects evaluated its safety and efficacy across COVID-19, autoimmune conditions, and cancer treatment — making it the most thoroughly human-tested immune-modulating peptide in this book.

Regulatory standing: Thymalfasin (Zadaxin) is approved and clinically used in China, Italy, Southeast Asia, and 35+ countries globally. It carries FDA orphan drug designation for four specific indications. In countries where it is approved, it is a prescribed pharmaceutical — not a grey-market research compound. Community use in countries where it is not approved sits in different legal and regulatory territory.

Science & Mechanism

TLR2 and TLR9 — The Dendritic Cell Activator

Tα1's mechanism is unusually well-characterised for a peptide of its age — decades of research have converged on a clear picture of how it modulates immune response without crude immunosuppression or wholesale activation.

Mechanism of Action

1

TLR2 and TLR9 activation on dendritic cells — Tα1 acts on toll-like receptors in both myeloid and plasmacytoid dendritic cells. This triggers downstream IRF3 and NF-κB signalling, leading to coordinated innate and adaptive immune activation. Unlike broad immune stimulants, TLR-targeted activation educates the immune response rather than simply amplifying it.

2

T-cell maturation and differentiation — induces IL-2 and B-cell growth factor production. Promotes differentiation of immature cord blood lymphocytes. Raises efficiency of macrophage antigen presentation. Partially normalises T-lymphocyte function and number — particularly relevant in immunodeficiency and post-chemotherapy immune suppression.

3

NK cell and cytokine regulation — activates natural killer cells. Induces IFN-γ and IL-2 production. In cancer contexts, the 2025 immunomodulation study confirmed direct anti-tumour T-cell enhancement in melanoma and breast cancer cell lines — upregulating CD86 expression.

4

Immune homeostasis — context-dependent — the defining feature of Tα1 is its bidirectional regulatory capacity. It can suppress an overactive immune response (cytokine storm in sepsis or severe COVID-19) while simultaneously stimulating an underactive one (post-chemotherapy immunosuppression, HIV-related immunodeficiency). This "multitasking protein" behaviour depends on the host's immune state.

5

Short half-life (~2 hours) — native Tα1 has a short serum half-life. Researchers have developed Tα1-Fc fusion proteins with 25-hour half-life (13x longer) that show stronger antitumour activity in mouse models — a next-generation development direction.

The TESTS Trial (BMJ, 2025) — the most important recent data point: The TESTS trial enrolled 1,106 sepsis patients in a randomised controlled trial of thymalfasin. The primary endpoint — 28-day mortality — was not significantly different overall. However, a pre-specified subgroup analysis showed significant benefit in patients aged 60 and over. This is not a failure of the compound but a signal about the population in which the immune restoration effect matters most: older patients whose immune systems are less capable of self-correction.

Community Voices

Immune Optimisation and Cancer Adjunct Use

Tα1's community following differs from most peptides in this book — it is more clinically oriented. Users are often people dealing with chronic viral illness (hepatitis, long COVID), cancer patients researching adjunct options alongside prescribed therapy, or older adults seeking immune restoration. The pharmaceutical-grade brand Zadaxin is available through legitimate medical channels in countries where it is approved.

Community ReportAnecdotal — not clinical evidence

"I used Tα1 as an adjunct during chemotherapy for breast cancer, sourced through my oncologist in Italy where Zadaxin is prescribed. The immune recovery between cycles felt noticeably faster — I was able to maintain the schedule without delays from immune suppression. My oncologist was tracking white cell counts throughout."

The chemotherapy immune support use case has the most clinical backing of any community application. Multiple trials show Tα1 as an adjunct to chemoimmunotherapy improving survival in HCC, melanoma, and lung cancer by reducing the immune suppression that forces treatment delays. Medical supervision with blood count monitoring is the appropriate framing.

Community ReportAnecdotal — not clinical evidence

"Sixty-four years old, chronic hepatitis B, using Tα1 as part of my treatment plan alongside antivirals. The subjective feeling is hard to quantify but my viral load markers have trended in the right direction. I'm aware this isn't proof — the combination makes isolation impossible — but I feel confident in the safety profile based on the trial data."

Hepatitis B is the original approved indication for thymalfasin. The evidence base in HBV is the most developed outside cancer adjunct use. Combination with antivirals is standard in countries where thymalfasin is prescribed.

Benefits & Evidence

Thirty Trials, Eleven Thousand Subjects

🦠

Hepatitis B and C — Original Indication

Phase 3 trials established efficacy in chronic hepatitis B — the original approved indication. In combination with antiviral therapy, thymalfasin improves viral suppression and immune response rates. Hepatitis C data shows synergy with interferon therapy. This remains the most robustly evidenced application.

● Strong — Phase 3 trials / Approved indication

🎗️

Cancer Immunotherapy Adjunct

HCC (liver cancer) after resection: thymalfasin significantly improved 5-year overall survival (82.9% vs 62.9%) and recurrence-free survival in a 47-month follow-up study. Melanoma, lung cancer: adjunct with chemoimmunotherapy improves survival. 2025 study confirmed direct anti-tumour T-cell enhancement in melanoma and breast cancer cell lines.

● Strong — multiple RCTs and long-term follow-up

🫁

COVID-19 and Sepsis

Widely used in China during COVID-19 pandemic. Retrospective analysis suggested ~60% mortality reduction in severe cases. The TESTS trial (BMJ 2025, n=1,106) found no significant 28-day mortality benefit overall, but significant benefit in patients 60+. Mixed results honestly reflecting the complexity of sepsis immune modulation.

● Moderate — positive signal in elderly; mixed in overall sepsis

🧬

HIV and Immunodeficiency

2024 study (BMC Infectious Diseases): Tα1 restores immune response in immunological non-responders living with HIV — people on antiretroviral therapy who fail to achieve CD4+ cell count recovery. Addresses a gap in ART that standard treatment does not solve.

● Moderate — HIV non-responder subpopulation data

👴

Immunosenescence and Vaccine Response

November 2025 review: Tα1 mitigates immunosenescence and improves vaccine response in the elderly. Age-related thymic involution reduces T-cell production — Tα1 partially reverses this by stimulating thymic output and dendritic cell function. The Refnot fusion protein (TNFα + Tα1) shows promise against age-related immune dysfunction.

● Moderate — growing evidence in ageing / immunosenescence

Safety First

Indistinguishable from Placebo

Mild

Injection site reactions — mild localised discomfort at subcutaneous injection sites. Generally transient. Consistent with any subcutaneous peptide injection.

Context

Use during active autoimmune disease — Tα1 modulates immune responses bidirectionally, but anyone with active autoimmune conditions should have medical oversight, as immune stimulation could theoretically affect disease activity.

Legal/Quality

Regulatory status varies by country — Zadaxin is a licensed pharmaceutical in 35+ countries. Outside those, grey-market versions lack pharmaceutical-grade quality controls. The safety data applies to pharmaceutical-grade preparations, not unverified research suppliers.

⚠ Warnings

The safety evidence applies to pharmaceutical-grade thymalfasin. Grey-market research compound quality is unverified — impurities and incorrect concentrations are possible.

Anyone using Tα1 as a cancer adjunct should do so with oncological oversight — not independently alongside prescribed treatment without disclosure to their medical team.

This entry is for educational purposes only and does not constitute medical advice.

Synergy Stack

Nutrients, Supplements & Exercise

Thymosin α-1 is an immune modulator that works through TLR2/TLR9 on dendritic cells. Its synergies focus on ensuring the immune system has the nutritional foundation to respond fully to the signal Tα1 is sending.

💊 Nutrients & Supplements

Zinc

15–25mg/day

Strong evidence

Thymosin α-1 activates T-cell maturation — zinc is required at every step of T-cell development. Deficiency creates a ceiling on immune response regardless of Tα1 stimulation. Test zinc levels first.

Vitamin D3

4000 IU/day with K2

Strong evidence

Vitamin D3 is essential for innate and adaptive immune function. Both Tα1 and vitamin D3 modulate dendritic cell activity — they work through overlapping immune regulation pathways. Most people in northern latitudes are deficient.

Selenium

100–200mcg/day

Moderate evidence

Selenoproteins are essential for immune cell activation and antioxidant defence in immune cells. Selenium deficiency impairs the very T-cell function Tα1 is trying to enhance.

Vitamin C

500–1000mg/day

Moderate evidence

Accumulates in immune cells at 50–100x plasma concentrations — essential for their function and proliferation. Supports the immune activation Tα1 stimulates.

🏃 Exercise & Lifestyle

Moderate regular exercise

30–45 minutes most days. Exercise at moderate intensity enhances immune surveillance and T-cell circulation — complementary to Tα1's T-cell activation. Very high intensity exercise can temporarily suppress immunity, counterproductive during Tα1 protocols.

Adequate sleep (non-negotiable)

7–9 hours. More immune cells are produced and activated during sleep than at any other time. Tα1's immune enhancement requires a sleep environment where immune activation can occur.

Stress management

Chronic stress elevates cortisol which directly suppresses T-cell function — counteracting Tα1's mechanism. Meditation, breathwork, or therapy are relevant co-interventions.

⏱ Timing & Protocol Notes

Tα1 is typically injected subcutaneously, often in cycles. Test zinc and vitamin D levels before starting and correct deficiencies — they are prerequisites, not optional additions.

Disclaimer: These recommendations are educational and based on the known mechanisms of each compound. Individual responses vary. Consult a qualified healthcare provider before changing your supplement or exercise regimen, particularly when using experimental peptides.

Synergy Stack

Nutrients, Supplements & Exercise That Enhance This Peptide

The compounds and practices below have evidence supporting synergy with this peptide — either working on the same biological pathway, providing essential co-factors, or creating the physiological conditions that amplify the peptide's effects. Evidence ratings reflect the strength of the supporting science.

💊 Nutrients & Supplements

Vitamin D3 4000–6000 IU daily

Vitamin D is an immune system regulator that works on many of the same dendritic cell and T-cell pathways as Thymosin α-1. Deficiency is extremely common and blunts immune function.

● Strong evidence

Zinc 15–25mg daily

Required for T-cell maturation and thymic function — directly relevant to Thymosin α-1's T-cell differentiation mechanism. Also supports thymulin activity simultaneously.

● Strong evidence

Selenium 100–200mcg daily

Essential for immune enzyme function and antiviral defence. Works alongside Thymosin α-1 in contexts like hepatitis B and viral immunity.

● Moderate evidence

Omega-3 (EPA/DHA) 2–3g daily

Modulates the inflammatory cytokine environment — reduces background inflammation so Thymosin α-1's immune calibration operates in less noise.

● Moderate evidence

Vitamin C 500–1000mg daily

Immune system co-factor required for immune cell function and antioxidant defence during immune activation.

● Moderate evidence

🏃 Exercise & Lifestyle

Moderate aerobic exercise 3–5x weekly

Regular moderate exercise improves immune surveillance and T-cell function — directly complementary to Thymosin α-1's immune restoration effects.

● Strong evidence

Avoid overtraining Monitor immune symptoms

Excessive high-intensity training transiently suppresses immune function (the "open window" effect). Counterproductive when trying to restore immune capacity.

● Strong evidence

Sleep (7–9 hours) Non-negotiable

Immune restoration happens primarily during sleep — Thymosin α-1's T-cell differentiation effects are most active during the immune maintenance window sleep provides.

● Strong evidence

⚠ Avoid or limit: Immunosuppressant drugs (used for autoimmune conditions or transplants) work counter to Thymosin α-1's immune-stimulating mechanism — use only under medical supervision in these contexts. Smoking directly impairs dendritic cell function, the primary target of Tα1.

The Honest Assessment

Where Thymosin α-1 Actually Stands

Thymosin α-1 occupies a unique position in this book: it is the immune peptide that has most successfully crossed from biohacker interest into legitimate mainstream medicine. It is prescribed by oncologists. It is approved by regulators. Its mechanism is well understood. Its safety data is extraordinary. The TESTS trial result — neutral on overall sepsis mortality, positive in elderly — does not diminish its standing; it refines the understanding of which patients benefit most.

The cancer adjunct data is the most compelling application: the HCC post-resection survival improvement (5-year OS 82.9% vs 62.9%) is a clinically meaningful outcome, not a surrogate endpoint. The immunological non-responder HIV data opens a therapeutic gap that standard ART does not address. The immunosenescence applications are the newest frontier and the most relevant to the broader anti-ageing community.

For those in countries where Zadaxin is approved: this is a medical decision with real physician support available. For those sourcing independently: the safety profile is reassuring, but the legal status and quality control question is real.

Editor's Summary

"Thymosin α-1 is the most clinically substantiated immune-modulating peptide in this book — 35+ country approvals, FDA orphan drug status, over 11,000 trial subjects, extraordinary safety profile. The cancer adjunct data is genuinely impressive. The HIV non-responder finding addresses a real gap. The TESTS sepsis trial gives an honest mixed result that refines rather than undermines the picture. If you're going to use any immune peptide with confidence, this is the one with the evidence base to back it."